Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
Italy
In shortRecordati Industria Chimica E Farmaceutica S.p.a. IN Breve Recordati S.p.a. is profitable.
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 31.0% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 24.4% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 29.0% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.36× | 46/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 4.18 | 79/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 29.7% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.22× | 100/100 |
| Years with positive free cash flow (last 5) | 2 of 2 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 2 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 1 | 100/100 |
| Revenue growth volatility | – | n/a |
| Operating margin volatility | 1.0% | 100/100 |
Weight in the score: 20%
Fiscal year 2021 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
The last 2 fiscal years from the company's annual reports.
EUR millions; negative values in parentheses.
| Fiscal year | FY20 | FY21 |
|---|---|---|
| Revenue | 1,449 | 1,580 |
| Cost of revenue | 407 | 428 |
| Gross profit | 1,042 | 1,152 |
| Research & development | 146 | 166 |
| Operating income | 469 | 490 |
| Pre-tax income | 456 | 463 |
| Income tax | 101 | 77 |
| Net income | 355 | 386 |
| Diluted EPS | €1.70 | €1.85 |
4.18 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Dec 31, 2023